133 related articles for article (PubMed ID: 12846895)
21. Current treatment standards and emerging strategies in mantle cell lymphoma.
Dreyling M; Hiddemann W;
Hematology Am Soc Hematol Educ Program; 2009; ():542-51. PubMed ID: 20008239
[TBL] [Abstract][Full Text] [Related]
22. Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
Hassan HM; Varney ML; Chaturvedi NK; Joshi SS; Weisenburger DD; Singh RK; Dave BJ
Leuk Lymphoma; 2016 Dec; 57(12):2874-2889. PubMed ID: 27074052
[TBL] [Abstract][Full Text] [Related]
23. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
25. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
26. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.
Wagenknecht B; Hermisson M; Eitel K; Weller M
Cell Physiol Biochem; 1999; 9(3):117-25. PubMed ID: 10494025
[TBL] [Abstract][Full Text] [Related]
28. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.
Sarkar A; Balakrishnan K; Chen J; Patel V; Neelapu SS; McMurray JS; Gandhi V
Oncotarget; 2016 Jan; 7(3):3461-76. PubMed ID: 26658105
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a new mantle cell lymphoma cell line, Mino.
Lai R; McDonnell TJ; O'Connor SL; Medeiros LJ; Oudat R; Keating M; Morgan MB; Curiel TJ; Ford RJ
Leuk Res; 2002 Sep; 26(9):849-55. PubMed ID: 12127561
[TBL] [Abstract][Full Text] [Related]
30. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
32. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C
Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
35. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
37. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R; Chubb S; Cheng T; Hawtin RE; Gandhi V; Plunkett W
Cancer Res; 2010 Aug; 70(16):6587-97. PubMed ID: 20663900
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
Park IW; Reddy MV; Reddy EP; Groopman JE
Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
[TBL] [Abstract][Full Text] [Related]
39. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
